Floatz logo

Tabelecleucel

Solid Organ Transplant Complications

Pierre Fabre MedicamentCell therapyPhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Solid Organ Transplant Complications cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

Tabelecleucel is also rated in:

Epstein-Barr virus-associated lymphoproliferative disorderDormant
BB
Indicative ·
66 / 100
View asset →
disease related to hematopoietic stem cell transplantDormant
BB
Indicative ·
66 / 100
View asset →
disease related to hematopoietic stem cell transplantDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →